Meeting
2015 ASCO Annual Meeting
Genetic variants of kinases suppressors of Ras (KSR) to predict tumor response to first-line cetuximab in patients with mCRC: Prospective analysis in the FIRE 3 trial.
Authors
Leonor Benhaim
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA
Leonor Benhaim , Wu Zhang , Takeru Wakatsuki , Armin Gerger , Dongyun Yang , David Paez , Yan Ning , Rita Elie El-Khoueiry , Fotios Loupakis , Pierre Oliver Bohanes , Sebastian Stintzing , Volker Heinemann , Heinz-Josef Lenz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Citation
J Clin Oncol 33, 2015 (suppl; abstr 3613)
DOI
10.1200/jco.2015.33.15_suppl.3613
Abstract #
3613
Poster Bd #
106
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Genetic variant of TWEAK to predict clinical outcome in mCRC patients (pts) treated with first line FOLFIRI and Bevacizumab (FOLFIRI/BEV) in FIRE-3 and TRIBE cohorts.
First Author: Anish Parekh
Poster
2014 ASCO Annual Meeting
Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial.
First Author: Volker Heinemann
Poster
2014 ASCO Annual Meeting
Genetic variants of TCF7L2 and AXIN2 predict gender and tumor location-dependent clinical outcome in FIRE-3 trial: A validation study.
First Author: Yan Ning
Poster
2023 ASCO Annual Meeting
RAS testing of circulating cell-free DNA (cfDNA) from tissue RAS/BRAF wild-type metastatic colorectal carcinoma (mCRC) patients: Preliminary data from the Liquid Biopsy Monoclonal Antibodies in mCRC (LIBImAb) study.
First Author: Anna Maria Rachiglio